Calidi Biotherapeutics, Inc.

CLDI Healthcare Biotechnology

Calidi Biotherapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $45,000.00. In the quarter to June 2026, EPS grew 90.8%, free cash flow grew 11.2% and total debt fell 7.87%, each against the same quarter a year earlier.

0.84 0.03 −3.45%
Market cap
$3.2M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
−85.83
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Current Ratio
1.68 1.92 1.59 2.12

+8 more quarters

Net Debt/EBITDA
0.89 1.56 1.19 2.07
Debt/Equity
0.24 0.15 0.21 0.11
Free Cash Flow per Share
(3.10) (6.40) (18.87) (13.91)
Book value per Share
2.21 7.66 13.98 23.47
Free Cash Flow
(4.39) (4.12) (5.07) (4.26)
Other line items

Show all line items

Columns are period end dates